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Summary 
Title:         Treatment of cardiac arrhythmias in the Emergency Department  
Name:       Haider Sabhan 
 
Cardiac arrhythmias, some of the most frequent diagnoses presenting at the emergency 
department, require a good and thorough understanding and quick recognition in the 
stressful emergency department environment.  
 
Despite dedicating significant time in training to the mechanisms and treatment of cardiac 
rhythm disturbances, most physicians are uncomfortable and lack confidence when faced 
with such clinical situations. Therefore, a solid understanding of the different causes and   
quick action is essential and can be lifesaving in the emergency room setting. 
 
Arrhythmias and conduction disorders are caused by abnormalities in the generation and/or 
conduction of electrical impulses in the heart. Symptoms such as dizziness, palpitations, and 
syncope are frequent complaints encountered by family physicians, internists, and 
cardiologists. In contrast to these ubiquitous complaints, which are generally benign, sudden 
cardiac death remains an important public health concern. 
 
Classification of arrhythmias is essential for the quick recognition and, thus, quick treatment. 
Currently, arrhythmias are divided simply as tachycardias and bradycardias. Bradycardias 
are further classified into heart block or simple bradycardia. Tachycardia, on the other hand, 
can be divided into two categories based on the width of the QRS complex: narrow complex 
(QRS duration is less than 120 milliseconds) or broad complex (QRS duration is more than 
120 milliseconds). 
 
In 1970, Dr. Vaughn-Williams, Oxford University, introduced the first classification of anti-
arrhythmic drugs. With regards to management of atrial fibrillation, Class I and III are used in 
rhythm control as medical cardioversion agents, while class II and IV are used as rate control 
agents. 
 
 
Keywords: arrhythmias, treatment, recognition, cardiac abnormalities, classifications  
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Introduction 
Not many things can raise the anxiety level in a physician more than a call to the emergency 
department about a patient who has a cardiac arrhythmia. Despite a significant amount of 
time throughout medical training being dedicated to understanding the mechanisms and 
treatments of cardiac rhythm disturbances, most physicians are uncomfortable knowing how 
to correctly approach these kinds of patients. 
 
Cardiac disorders are the most common clinical cases presenting in the emergency room. 
Therefore, a solid understanding of the different causes and quick reaction to these clinical 
situations is lifesaving in the stressful emergency room environment.  
 
The current annual incidence of sudden cardiac death in the United States of America is 
likely to be in the range of 180,000–250,000 per year. Coinciding with the decreased 
mortality from coronary artery disease, there is additional evidence pointing toward a 
significant decrease in rates of sudden cardiac death in the US during the second half of the 
twentieth century. However, the alarming rise in the worldwide prevalence of obesity and 
diabetes in the first decade of the 21st century would indicate that this favorable trend is 
unlikely to persist. We are likely to witness a reemergence of coronary artery disease and 
heart failure and, as a result, cardiac death will have to be confronted as a shared and 
unselective worldwide public health problem (1). 
 
The healthy heart always beats in a regular, coordinated manner, due to the electrical 
impulses generated and spread by myocytes. Theses myocytes with special electrical 
properties trigger a sequence of organized myocardial cell contractions. Arrhythmias and 
conduction disorders are caused by abnormalities in the generation or conduction of these 
electrical impulses or both. 
Any heart disorder, including congenital abnormalities of structure (eg, accessory 
atrioventricular connection) or function (eg, hereditary ion channelopathies), can disturb a 
heart’s rhythm. Systemic factors that can cause or contribute to a rhythm disturbance include 
electrolyte abnormalities (particularly low K or Mg), hypoxia, hormonal imbalances (eg, 
hypothyroidism, hyperthyroidism), and drugs and toxins (eg, alcohol, caffeine). 
Cardiac dysrhythmia is any of a group of conditions in which the electrical activity of the heart 
is irregular, faster, or slower than normal (1). The term tachycardia pertains to a heart rate 
above 100 beats per minute and bradycardia describes a heart rate below 60 beats per 
minute. 
Although many arrhythmias are not life-threatening, some can cause serious impairment of 
the cardiac function, with the worst case scenario being cardiac arrest (1). 
Arrhythmias can occur in the upper chambers of the heart (atria), in the lower chambers of 
the heart (ventricles), or at the level of the atrioventricular junction.  
 
Cardiac arrhythmias are one of the most common causes of death in the Western world, and 
specifically, of sudden death. Some arrhythmias, such as atrial fibrillation, may be 
asymptomatic, but still may predispose the patient to potentially life-threatening conditions 
such as stroke or embolism. 
 
Symptoms such as dizziness, palpitations, and syncope are frequent complaints 
encountered by family physicians, internists, and cardiologists. Although these presenting 
complaints are generally benign, arrhythmias may also present with sudden cardiac death, 
making arrhythmias an important public health concern. Statistics from the Centers for 
Disease Control and Prevention (CDC) have estimated that up to 50% of patients have 
sudden death as the first manifestation of cardiac disease. 
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This graduate thesis will explain the basics of cardiac anatomy and pathophysiology. The 
thesis will start with the presenting symptoms, classification, and further explore the 
treatments of different types of arrhythmias.  
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Anatomy and Physiology of the Heart 
Anatomy of the heart 
At the junction of the superior vena cava and the lateral right atrium is a cluster of cells that 
generate the initial electrical impulse of each normal heartbeat, called the sinoatrial (SA) or 
sinus node, can be found (2,3,4). The electrical discharge of these pacemaker cells 
stimulates adjacent cells, leading to further stimulation of successive regions of the heart in 
an orderly sequence. Impulses are transmitted through the atria to the atrioventricular (AV) 
node via preferentially conducting internodal tracts and unspecialized atrial myocytes (Figure 
1). The AV node is located on the right side of the interatrial septum. It has a slow conduction 
velocity and thus delays impulse transmission (2,3,4). AV nodal transmission time is heart-
rate–dependent and is controlled by autonomic tone and circulating catecholamines to 
maximize cardiac output at any given atrial rate. 
 
 
Figure 1: The normal impulse transmission through the heart. 
Dr. Dale Dubin -  Rapid interpretation of ECG 6th edition 2000 - page 13 
 
The atria are electrically insulated from the ventricles by the annulus fibrosus (a thick fibrous 
membrane that prevent any passage of impulses) except in the anteroseptal region. There, 
the bundle of His, a continuation of the AV node, enters the top of the interventricular 
septum, where it bifurcates into the left and right bundle branches and terminates as the 
Purkinje fibers. The right bundle branch conducts impulses to the anterior and apical 
endocardial regions of the right ventricle. The left bundle branch fans out over the left side of 
the interventricular septum (2,3,4). Its anterior portion (left anterior hemifascicle) and its 
posterior portion (left posterior hemifascicle) stimulate the left side of the interventricular 
septum, which is the first part of the ventricles to be electrically activated. Thus, the 
interventricular septum depolarizes left to right, followed by near-simultaneous activation of 
both ventricles from the endocardial surface through the ventricular walls to the epicardial 
surface (2,3,4). 
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Physiology of the heart 
Basic understanding of normal heart physiology is essential for the comprehension of the 
rhythm disturbances that will be explained in the following section.  
  
Figure 2: Standard model of a cardiomyocyte action potential Sherwood L. 2012 Human Physiology 
page 310 
The passage of ions across the myocyte cell membrane is regulated by specific ion 
channels. This movement of ions causes cyclical depolarization and repolarization of the cell. 
This movement of ions across the myocyte cell membrane is called an action potential 
(Figure 2). The action potential of a working myocyte begins when the cell is depolarized 
from its diastolic −90 mV transmembrane potential to a potential of about −50 mV (5).  
At this threshold potential, voltage-dependent fast Na channels open, causing rapid 
depolarization mediated by Na influx down its steep concentration gradient. The fast Na 
channel is rapidly inactivated and Na influx stops, but other time- and voltage-dependent ion 
channels open, allowing Ca to enter through slow Ca channels (a depolarizing event) and K 
to leave through K channels (a repolarizing event). At first, these 2 processes are balanced, 
maintaining a positive transmembrane potential and prolonging the plateau phase of the 
action potential. During this phase, Ca entering the cell is responsible for electromechanical 
coupling and myocyte contraction. Eventually, Ca influx ceases, and K efflux increases, 
causing rapid repolarization of the cell back to the −90 mV resting transmembrane potential. 
While depolarized, the cell is resistant (refractory) to a subsequent depolarizing event. 
Initially, a subsequent depolarization is not possible (absolute refractory period), and after a 
partial but incomplete repolarization, a subsequent slow depolarization is possible (relative 
refractory period) (4,5). 
There are 2 general types of cardiac tissue:  
 Fast-channel tissues 
 Slow-channel tissues 
Fast-channel tissues (working atrial and ventricular myocytes, His-Purkinje system) have a 
high density of fast Na channels and have action potentials characterized by little or no 
spontaneous diastolic depolarization (and thus very slow rates of pacemaker activity), very 
rapid initial depolarization rates (and thus rapid conduction velocity), and a loss of 
refractoriness coinciding with repolarization. As a result, these tissues have short refractory 
periods and the ability to conduct repetitive impulses at high frequencies (4,5).  
Slow-channel tissues (SA and AV nodes) have a low density of fast Na channels and have 
action potentials characterized by more rapid spontaneous diastolic depolarization (and thus 
more rapid rates of pacemaker activity), slow initial depolarization rates (and thus slow 
conduction velocity), and a loss of refractoriness that is delayed after repolarization. Thus 
these tissues have long refractory periods and the inability to conduct repetitive impulses at 
high frequencies. About 1% of the cardiac muscle cells in the heart are responsible for 
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forming the conduction system that sets the pace for the rest of the cardiac muscle cells 
(4,5). 
Normally, the SA node has the most rapid rate of spontaneous diastolic depolarization, so its 
cells produce spontaneous action potentials at a higher frequency than other tissues. Thus, 
the SA node is the dominant automatic tissue (pacemaker) in a normal heart (4). If the SA 
node does not produce impulses, tissue with the next highest automaticity rate, typically the 
AV node, functions as the pacemaker. Sympathetic stimulation increases the discharge 
frequency of pacemaker tissue, and parasympathetic stimulation decreases it. 
 
Normal rhythm 
The resting sinus heart rate in adults is usually 60 to 100 beats/min. Slower rates (sinus 
bradycardia) occur in young people, particularly athletes, and during sleep. Faster rates 
(sinus tachycardia) occur with exercise, illness, or emotion through increased sympathetic 
output and increased circulating catecholamines. Normally, a marked daytime variation in 
heart rate occurs, with lowest rates just before early morning awakening. A slight increase in 
rate during inspiration with a decrease in rate during expiration (respiratory sinus arrhythmia) 
is also normal; it is mediated by fluctuations in vagal tone and is particularly common among 
healthy young people. The oscillations diminish but do not entirely disappear with age. 
Absolute regularity of the sinus rhythm rate is pathologic and occurs in patients with 
autonomic denervation (eg, in advanced diabetes) or with severe heart failure (3,4). 
Electrocardiogram 
An electrocardiogram (ECG) is a recording of the electrical activity of the heart. Traditionally 
this is in the form of a transthoracic (across the thorax or chest, figure 3) interpretation of 
the electrical activity of the heart over a period of time, as detected by electrodes attached to 
the surface of the skin and recorded or displayed by a device external to the body (6).  
Most cardiac electrical activity is represented on the ECG (Figure 4). The P wave represents 
atrial depolarization. The QRS complex represents ventricular depolarization, and the T wave 
represents ventricular repolarization. Atrial repolarization is not seen on the ECG because it 
occurs during the QRS depolarization. 
 
 
Figure 3: Figure showing a patient connected to the 10 electrodes necessary for a 12-lead ECG. 
Author: Madhero, March 2009 
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The PR interval (from the beginning of the P wave to the beginning of the QRS complex) is 
the time interval from the beginning of atrial activation to the beginning of ventricular 
activation. Much of this interval reflects the slowing of impulse transmission in the AV node. 
The R-R interval (time between 2 QRS complexes) represents the ventricular rate (6). This 
interval, as read by doctors on an ECG, is used to determine a patient’s heart rate. The QT 
interval (from the beginning of the QRS complex to the end of the T wave) represents the 
duration of ventricular depolarization. Normal values for the QT interval are slightly longer in 
women; they are also longer with a slower heart rate.  
 
  
Figure 4: Different waves, segments and intervals of an Electrocardiogram.  
Wagner, GS. Marriott’s Practical Electrocardiography (11th edition), Lippincott Williams & 
Wilkins 2007. Photo by Ed Burns. 
 
 
Table 1: Pathological patterns seen on ECG, followed by potential causes. 
Kumar and Clark – Clinical Medicine 8th edition, chapter 14 – 2012. 
Shortened QT-interval Hypercalcemia, genetic abnormalities, 
hyperkalemia  
Prolonged QT-interval Hypocalcemia, genetic abnormalities, 
medications 
Flattened or inverted T-waves Coronary ischemia, hypokalemia, LV 
hypertrophy, Digoxin 
Hyperacute T-waves 
 
Possibly the first presentation of MI  
Peaked T-waves, wide QRS, 
prolonged PR, QT short 
Hyperkalemia – treat with calcium 
chloride, glucose and insulin. 
Prominent U-waves 
 
Hypokalemia  
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Classification of Cardiac Arrhythmias 
 
The classification of arrhythmias is essential for quick recognition and prompt treatment. We 
classify arrhythmias simply as tachycardias (heart rate greater than 100 beats per minute) 
and bradycardias (heart rate less than 60 beats per minute).  
 
Bradycardias are further classified into heart block or simple bradycardia (7). Tachycardias, 
on the other hand, can be divided into two categories based on the width of the QRS 
complex (Figure 5). If the QRS duration is less than 120 milliseconds, the tachyarrhythmia is 
narrow complex. If QRS duration is longer than 120 milliseconds, it is considered broad 
complex. When determining the QRS width, we always compare the findings on at least two 
different leads on the ECG, as a single lead interpretation is often insufficient (7).  
 
If the arrhythmia has a narrow QRS complex, it is by definition a supraventricular tachycardia 
(SVT). These arrhythmias are usually benign, and often the patient can be treated and 
discharged from the emergency department to complete the evaluation as an outpatient. If 
the tachycardia has a wide QRS complex, it is either a ventricular tachycardia (VT), 
Ventricular fibrillation, or, a SVT with aberrant conduction or pre-excitation (7,8).  
 
 
 
Figure 5: Classification of arrhythmias. Author: Sion Williams, March 2011, BSUH  
 
 
 
 
 
 
Broad complex tachycardia 
In contrast to the benign narrow complex tachycardias, these tachycardias are usually 
malignant and require hospitalization for further treatment. 
It is extremely important to distinguish between VT and SVT as medication given for the 
treatment of SVT may be harmful or even fatal to a patient in VT. 
The easiest way to recognize VT includes a QRS width greater than 120 milliseconds, a 
QRS axis in frontal plane (far left or right), concordance of QRS complexes across the 
precordium, and a time from onset of the R-wave to the nadir of S-wave in any precordial 
lead of more than 100 milliseconds (8).  
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Clinical data collected from the patient is also beneficial in establishing the correct diagnosis. 
A history of a previous myocardial infarction or structural heart disease is highly suggestive 
that the wide complex tachycardia is VT (8).  
Usually, a proper and detailed history of illness and physical exam of the patient is enough to 
establish the presence or absence of structural heart disease in the patients. However, if 
history taking and physical examination is insufficient to give a concrete diagnosis, a 
transthoracic echocardiogram (TTE) will give more detailed information regarding the 
patient’s cardiac anatomy and function.   
Regarding the hemodynamic stability of the patient; Steinman and colleagues (9) 
demonstrated that VT is the correct diagnosis in 85% of patients who present with a wide 
complex tachycardia with normal hemodynamic stability.  
 
Supraventricular tachycardias (SVT) 
Supraventricular tachycardias are tachycardias that arise from foci of inappropriate electrical 
activity originating at or above the AV-node. As a systemic approach, every doctor should 
have in mind the different causes of a narrow complex tachycardia.  
An easy algorithm to remember is to think anatomically, starting from where the heartbeat 
originates, at the SA-node, and ending at the atrioventricular AV-node. SVT can be caused 
by sinus tachycardias, atrial tachycardias, atrial flutter, atrial fibrillation, junctional 
tachycardia, AV nodal reentry, or AV reciprocating tachycardia using a bypass tract (10). 
It is important to diagnose those different types of arrhythmias because treatment is specific 
for each one of them. For example, appropriate sinus tachycardia is treated by identifying the 
cause of the arrhythmia, such as fever, hypovolemia, or hyperadrenergic states rather than 
simply slowing the heart rhythm with beta-blockers. Patients, usually young adults, who have 
SVT usually present with palpitations (10). They notice a rapid heart rate and seek medical 
attention if it persists. They usually give a history of paroxysmal symptoms that have been 
present for years. Initial evaluation in the emergency department includes an ECG, history, 
and complete physical examination. If symptoms persist, a Valsalva maneuver or carotid 
sinus massage, might be useful in either terminating the arrhythmia or causing the loss of 
ventricular capture for a single beat to allow diagnosis of the arrhythmia mechanism (18). If 
the arrhythmia is not terminated by these bedside maneuvers, adenosine (6 or 12 mg 
intravenously) will usually cause AV nodal block, either terminating the arrhythmia or allowing 
the visualization of the underlying mechanism. 
 
Adenosine has a rapid onset and short duration of action with a half-life of less than 10 
seconds. It is important to administer the adenosine rapidly and to follow the infusion with a 
flush of saline for a better effect. The usual side effects of flushing, dyspnea, and chest 
discomfort are usually short lived (11). Other drugs that could be used as AV-blocking agents 
include beta-blockers and calcium-channel blockers. These drugs have a longer half-life and 
their own potential side effects, leading to the preferential usage of adenosine by emergency 
physicians due to its quick onset of action and short half-life. 
 
Most SVTs are benign and can be treated in the emergency department, with the patient 
being discharged soon after (12,14). However, if a patient presents with new-onset atrial 
fibrillation, they cannot be discharged so quickly. This arrhythmia presents as an irregularly 
irregular ventricular rate with QRS complexes of variable duration. This arrhythmia may 
present with hemodynamic compromise if the ventricular rate is sufficiently fast. When 
treating this arrhythmia, calcium-channel blocking drugs and adenosine should be avoided. 
These drugs often increase conduction through the bypass tracts, while decreasing 
conduction through the AV node. The general effect causes an increase in the ventricular 
response rate and can cause hemodynamic compromise (13,14). 
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Atrial flutter and atrial fibrillation 
Atrial fibrillation (AF) has its own special weight, as it’s the most common abnormal heart 
rhythm. In the majority of patients, AF will be an accidental finding as it can be asymptomatic 
(15). However, it patients may also present with complaints of palpitations or chest pain, or 
episodes of fainting (15). AF can result in a reduction of cardiac output or formation of blood 
thrombi in the heart chambers. These thrombi may break apart, causing emboli to be 
released into circulation. The risk of stroke is increased 5 times in individuals with AF.  
Atrial flutter and atrial fibrillation (Figure 6) represent a special challenge to the emergency 
department physician. Both arrhythmias may present as incidental findings in a patient who 
presents to the emergency department for other complaints. These arrhythmias are common 
in the general population, with the incidence increasing with age. For both, hypertension is 
considered the most common alterable risk factor. 
 
 
 
 
Figure 6: Pay attention to the missing p-waves and irregular beat in atrial fibrillation and the 
sawtooth pattern of the atrial flutter. John R. Hampton – 150 ECG problems 3rd edition 2008 
page 47. 
 
 
Ventricular tachycardia 
 
This is a potentially life-threatening arrhythmia that emergency department physicians dread, 
due to its potential of evolving into VF, asystole, or sudden cardiac death (16).  
Most patients who present with these arrhythmias have underlying heart disease. If the 
patient is hemodynamically unstable, perform an electrical cardioversion as quickly as 
possible. The rate of survival depends on the speed of cardioversion (16). 
The most common cause of VT is myocardial scarring from a previous myocardial infarction. 
This scar is composed of fibrous tissue, meaning that it cannot conduct electrical activity, so 
there is a potential circuit around the scar that results in the tachycardia.  
Patients who will be successfully treated will have to be admitted to the cardiology 
department for further evaluation and treatment. 
 
Bradycardia 
Bradycardias are often asymptomatic, and occur more often in older people. A rate below 50 
beats per minute can cause fatigue, weakness, dizziness and rarely fainting. A heart rate 
below 40 beats per minute is called absolute bradycardia. 
Bradycardia usually occur during sleep, and in well-trained athletes, and is considered 
normal. 
The mechanisms that act on the heart and cause bradycardia can either be depressed 
automaticity of the heart, conduction block, or escape pacemakers. 
For the emergency room physician, and our algorithm, we classify bradycardias as disorders 
of the SA-node and disorders of the AV-node. With SA-node dysfunction (Sick sinus 
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syndrome), there may be disordered automaticity or impaired conduction of the impulse from 
the sinus node into the surrounding atrial tissue (an "exit block"). Second-degree sinoatrial 
blocks can be detected only by use of a 12-lead EKG (17). It is difficult and sometimes 
impossible to assign a mechanism to any particular bradycardia, but the underlying 
mechanism is not clinically relevant to treatment, which is the same in both cases of sick 
sinus syndrome: a permanent pacemaker. 
AV-node disturbances (AV-blocks) may result from impaired conduction in the AV node, or 
anywhere below it, such as in the Bundle of His. The clinical relevance affecting to AV blocks 
is greater than that of sinoatrial blocks (17). 
 
 
Figure 7: A comparison of the three different AV blocks to the normal ECG. John R. 
Hampton – 150 ECG problems 3rd edition 2008 page 17.   
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Diagnosis and Presentation of Cardiac Arrhythmias 
The presentation of cardiac arrhythmias can range from none to syncope, loss of 
consciousness, or sudden cardiac death. In general, the more severe symptoms usually 
present in patients with underlying structural heart disease.  
For example, patient with an anatomically normal heart may have sustained monomorphic 
VT that is completely tolerated without any symptoms of syncope. In contrast, another patient 
with left ventricular dysfunction with VT may be hemodynamically unstable or have marked 
symptoms present.  
Different arrhythmias have different symptoms. Some of the common presenting symptoms 
in the emergency department are lightheadedness, shortness of breath, dizziness, syncope, 
fluttering or palpitations, pounding, chest discomfort, and painful extra beats.  
For the experienced physician, some descriptions of symptoms can raise the index of 
suspicion and provide some differential diagnoses about the type of arrhythmia. If a young 
person presents with a sustained regular palpitations without any evidence of structural heart 
disease, the first differential in mind should be SVT caused by AV-nodal re-entry or SVT 
caused by an accessory pathway. An isolated premature beat, again in a normal heart, 
suggests premature atrial contractions (PAC) or premature ventricular contractions (PVC). 
 
Syncope has a vast list differential diagnosis and requires a proper history taking and 
physical exam. But again, the presentation of syncope in the setting of noxious stimuli such 
as pain, particularly when preceded by vagal-type symptoms (nausea, vomiting, 
diaphoresis), suggests neurocardiogenic or vasovagal syncope (18). 
 
The most common symptom of arrhythmia is palpitation - an abnormal awareness of 
heartbeat. This feeling could be infrequent, frequent or continuous. Some of this arrhythmias 
are harmless but some predispose to adverse outcomes.  
The same is with silent arrhythmias. For example, AF, can be silent until the patient presents 
with stroke, but some are symptomatic continuously, but never increase the mortality or 
disability.  
 
Bradyarrhythmias are usually well tolerated. But when the heartbeat is too weak to produce 
sufficient cardiac output, blood pressure drops and may cause lightheadedness, dizziness, or 
syncope.   
 
Although some emergency physicians feel comfortable dealing with arrhythmias and 
recognize the common signs, all patients require an electrocardiogram (ECG) to establish 
tbhe diagnosis of an arrhythmia (19). Simple auscultation of the heart is never enough.  
A 24 hour ECG, called a Holter monitor, may assist in confirming the diagnosis when the 
arrhythmia occurs sporadically, as is often the case.  
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Treatment of Arrhythmias in the emergency department 
Emergency treatment of bradyarrhythmias 
As previously mentioned, bradyarrhythmias are arrhythmias when the heart rate is below 60 
beats per minute. This can be normal in the majority of people and require no further 
treatment. However, a ventricular rate less than 40 beats per minute usually requires 
emergency treatment (2,3,4).  
The first step in the approach to a bradyarrhythmic patient is to try to find the cause of the 
bradyarrhythmia, e.g.: electrolyte disturbances, excessive vagal stimulation, and pericardial 
tamponade.  
The next step will be determined by the hemodynamic stability of the patient. Severe 
bradycardia with loss of consciousness should be treated with resuscitation immediately, 
until a temporary pacemaker is available.  
The following is an algorithm for the emergency treatment of bradyarrhythmias:  
 
 
 
Figure 8: Algorithm for fast treatment of bradyarrhythmia. European Resuscitation Council 
Guidelines for Resuscitation 2005. Resuscitation 2005; 67: 39–86.  
 
As seen in Figure 8, for a symptomatic but hemodynamically stable patient, the treatment of 
choice is atropine (20).  
Atropine is an antimuscarinic agent that is given for bradycardia, asystole, and AV-block 
above the bundle of HIS. It is given at a dosage of 0.5 mg every 2-5 minutes, up to a 
maximum dose of 0.04mg/kg. An easier way to think of this, is 3 mg for every 70kg.  
The contraindication for atropine, is an AV-block below the bundle of His, meaning Mobitz 
type 2 or third-degree AV-block with a substituted rhythm and a widened QRS-complex.  
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In those patients, atropine can cause paradoxical bradycardia. In this situation, 
catecholamines should be given to the patient, until a pacemaker can be implanted. The 
catecholamines used in clinical practice are adrenaline (0.1 mg IV) and orciprenaline (0.5 mg 
IV). 
 
Emergency treatment of tachyarrythmias 
Tachycardia is when the heart rate is above 100 beats per minute. A heart rate between 100-
150 bpm is called a simple tachyarrhythmia, while a heart rate between 150-250 bpm is 
called a paroxysmal tachyarrhythmia. The arrhythmias with the fastest heart rates are atrial 
flutter with 250-350 bpm and atrial fibrillation with greater than 350 bpm. Patients with heart 
rates above 150 bpm usually present with symptoms to the emergency department. 
The first step in the treatment of tachyarrhythmias will always depend on the hemodynamic 
stability of the patient.  
 
 
Figure 9: Algorithm for treatment of tachyarrhythmia. European Resuscitation Council 
Guidelines for Resuscitation 2005. Resuscitation 2005; 67: 39–86.  
 
Hemodynamically unstable patients are those presenting with shock, alteration of 
consciousness, or pulmonary edema. This patient group should be treated as quickly as 
possible with intravenous antiarrhythmic agents or cardioversion/defibrillation (20).  
Different arrhythmias will respond to different energies of defibrillation. Fibrillation and flutter 
usually respond to lower energies of 100 joules, while polymorphic ventricular tachycardia or 
VF should be treated with defibrillation energies of 200-300 joules. If the usage of lower 
defibrillation energies fails, which is often the case, then higher energies (360 J) should be 
tried.  
In addition to the defibrillation, IV administration of amidarone (150-300 mg IV) should be 
given (recommendation from a prospective, randomized study) (21).  
If a patient is conscious, hemodynamically unstable, and requires defibrillation, a sedative or 
analgesic should be given prior to defibrillation. 
 
A hemodynamically stable patient is treated with medications. The emergency physician 
should monitor the patient closely all the time and the patient should be placed on ECG 
monitoring. 
The ECG will help the doctor to determine which type tachycardia is present; the type of 
tachyarrhythmia dictates the type of pharmaceutical treatment (22).  
The width of the QRS is the deciding criteria for the classification of our arrhythmias.  
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A narrow QRS complex is considered to reflect physiological anterograde conduction in the 
His-Purkinje system, so we presume that the patient will have a supraventricular tachycardia 
originating above the bundle of His.  
On the other hand, a wide QRS complex is an indication of ventricular tachycardia and 
ventricular fibrillation (22).  
 
Antiarrhythmic drugs 
The Cardiac Arrhythmia Suppression Trial (CAST-study), published in 1989, changed the 
entire use of antiarrhythmic drugs.  
The drugs that were used in the study – moricizine, flecainide, encainide – were known to 
have ventricular arrhythmia suppression properties. However, CAST study demonstrated an 
increase mortality in patients treated with the wrong antiarrhythmic drug for the wrong 
arrhythmia (23).  
In 1970, Dr. Vaughn-Williams from Oxford University, introduced the first classification of 
anti-arrhythmic drugs. With regards to management of atrial fibrillation, Class I and III are 
used in rhythm control as medical cardioversion agents, while class II and IV are used as 
rate control agents. There are five main classes in the Vaughan-Williams classification. 
 
Table 2: Discerption of the different classes of antiarrhythmic drugs.  
Singh Vaughan Williams 1970 Oxford Univeristy. From Chaudhry G, Muqtada MD, Haffajee 
2000;28:N158-N164. 
Class Mechanism of Action Example Clinical indications 
Ia Na-channel blockers – 
intermediate 
association/dissociation 
Quinidine 
Procainamide 
Disopyramide 
-Ventricular arrhythmias 
-Prevention of paroxysmal recurrent atrial 
fibrillation 
-Procainamide in WPW-syndrome 
Ib Na-channel blockers – fast 
association/dissociation 
Lidocaine 
Tocainide 
 
-Ventricular tachycardia 
Ic Na-channel blockers – slow 
association/dissociation 
Flecainide -Prevents paroxysmal atrial fibrillation 
-Treats recurrent tachyarrythmias 
II B-blockers  Cardeviol 
Propanolol  
Timolol 
Atenolol 
Bisoprolol 
-Decrease MI mortality 
-Prevent recurrence of tachyarrythmias 
-Propanolol has some class I action 
III K-channel blockers Amiodarone 
Sotalol 
Ibutiide 
-WPW-syndrome 
-Sotalol is given for ventricular tachycardia and 
AF 
-Ibutilide is given for Atrial flutter 
IV Ca-channel blockers Verpamil 
Diltiazem 
-Prevent recurrence of Paroxysmal 
supraventricular tachycardia 
-Reduce ventricular rate in patients with AF 
 
 
Class I drugs 
The class I antiarrhythmic agents block sodium channels and interfere with the cardiac action 
potential. These agents are also called membrane-stabilizing agents, as they decrease the 
excitogenicity of the plasma membrane. 
Class I agents are divided into 3 groups, based upon their effect on the length of the action 
potential (24,25). 
 Ia lengthens the action potential (right shift) 
 Ib shortens the action potential (left shift) 
 Ic does not significantly affect the action potential (no shift) 
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             Class Ia                                                   Ib                                                Ic 
 
Figure 10: Class I agents and their effect on action potential. 
Milne JR, Hellestrand KJ, Bexton RS, Burnett PJ, Debbas NM, Camm AJ (February 1984). 
 
Class II drugs 
These agents act by blocking the effect of catecholamines at B1-adrenergic receptors, which 
will lead to decreased sympathetic activity on the heart (24).  
The most common indication for the use of these agents is supraventricular tachycardias.  
Most SVTs are caused by a reentrant circuit involving the AV node or use the AV node to 
conduct to the ventricle. Therefore, long-term treatment is directed at decreasing conduction 
through the AV node. Beta-blockers and calcium channel blockers are predominantly 
valuable for treating these arrhythmias. Once patients have been stabilized in the emergency 
department, they can usually be discharged on either a long acting beta-blocker or calcium-
channel blocker to complete their evaluation in the outpatient clinic. 
 
Class III drugs 
Class III agents act upon and block the potassium channels, which prolongs the 
repolarization and action potential (26). Since these agents do not affect the sodium channel, 
conduction velocity is not decreased. They are mostly described for the prevention of re-
entry arrhythmias. The effect of slowed atrial-ventricular myocyte repolarization usually leads 
to a prolonged QT-interval that can be obtained by the emergency physician (26).  
 
Class IV drugs 
Class IV agents act on the AV-node, blocking its calcium channels, resulting in prolonged 
AV-nodal conduction time. This causes a reduction in the contractility of the heart (negative 
inotropic effect). 
In contrast to beta-blockers, they allow the body to retain adrenergic control of heart rate and 
contractility (27).  
 
Usually, type Ia and III agents are initiated in the hospital with patient monitoring. Ic agents, 
however, are safe when used in a normal heart, i.e.: in the absence of structural heart 
anomalies. Amidorone, because of its long half-life (43 days), can be given at low doses in 
an outpatient setting, in the absence of bradycardia or left ventricular dysfunction. 
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Pacemakers and Defibrillators 
The implementation of a pacemaker requires specific indications according to the American 
College of Cardiology (ACC) and American Heart Association (AHA) guidelines.  
The correlation of symptoms with underlying bradyarrhythmias or heart blocks type 2 and 3 is 
required (29).  
The implantable cardioverter-defibrillator (ICD) is indicated for sustained VT or VF, survivors 
of cardiac arrest, or sustained monomorphic VT (29).  
Based on the MADIT II study, ICDs will routinely be implanted in patients with LV 
dysfunction, EF of less than 35%, and a previous myocardial infarction. The emergency 
indications for ICD implantation include patients with syncope who have dilated 
cardiomyopathy, patients who have hypertrophic obstructive cardiomyopathy, and especially 
patients who are at high risk for sudden cardiac death (family history of sudden cardiac 
death, syncope, non-sustained VTs).  
 
In the last 50 years, since the development of the pacemaker, there has been vast 
improvement in a pacemaker’s functionally and longevity (28).  
The pacemakers used today can last more than 10 years and pacemaker leads constantly 
improving. Unfortunately, in some instances leads do need to be changed due to a 
manufacturing defect or secondary to infection. Lead extraction, after a long time, is usually 
problematic due to being heavily fibrosed by endovascular tissue.  
The ICDs used today have a battery life of 6-8 years, with improvements to battery life in 
development (30). Patients with an implanted ICD usually need testing of their pacing every 
6-12 months. 
An ICD can terminate VT or VF with a shock, but it can also terminate sustained VT with anti-
arrhythmic pacing.  
 
Defibrillators can be single chamber or dual chamber. Single chamber devices are 
recommended for patients with severe LV dysfunction, normal and intact SA- and AV-nodes, 
and have no indication for pacing.  
Dual chamber devices are reserved for patients with an abnormal SA- or AV-node or 
conduction system who are prone to frequent episodes of supraventricular arrhythmias, such 
as atrial fibrillation (2). 
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Atrial Fibrillation 
Atrial fibrillation (AF) is the most common sustained abnormal heart rhythm worldwide, with 
an estimated 9 million people (1-2% of the general population) currently affected in Europe 
and USA (32,36). 
AF has a strong association with other cardiovascular diseases, such as coronary heart 
diseases, heart failure, valvular heart disease, diabetes mellitus, and most commonly, 
hypertension (34).  
It is characterized by an irregular and rapid heartbeat caused by an unknown mechanism.  
The normal impulses generated by the SA-node are overwhelmed by disorganized electrical 
impulses originating in the roots of the pulmonary veins, leading to irregular conduction of 
ventricular impulses that generate the heartbeat.  
Genetics, atrial ischemia or inflammation, metabolic or hemodynamic stress are all claimed 
to be risk factors for the development of AF.  
The primary factors determining AF treatment (31) are the duration of the fibrillation and 
evidence of hemodynamic instability. Cardioversion is indicated with new onset AF (onset 
within 48 hours) and in patients with hemodynamic instability. If rate and rhythm control 
cannot be maintained by medication or cardioversion, it may be necessary to perform 
radiofrequency ablation (RFA) of abnormal electrical pathways.  
AF is associated with a 5 times increased risk for stroke (33), and one in five strokes is 
attributed to this arrhythmia. Strokes caused by cardiogenic emboli are associated with high 
mortality, and those who do survive, are usually left with great disability. 
The reason for why we lack an early recognition of AF is the “silent” nature of this rhythm 
disturbance. 
 
Clinically, and in the emergency room, we distinguish five different types of AF, based on the 
presentation and duration of the arrhythmia:  
1. First diagnosed (resent onset) 
2. Paroxysmal AF 
3. Persistent AF 
4. Long-standing persistent AF 
5. Permanent AF 
 
The first type, first diagnosed, is given for every patient with newly diagnosed AF, 
irrespective of the duration of the arrhythmia or presence of related symptoms.  
The second type, paroxysmal AF, is usually self-terminating within 48 hours, a time which is 
clinically important regarding the treatment. Persistent AF, the third type, is diagnosed when 
an AF episode lasts longer than 7 days or requires termination by cardioversion – either by 
drugs or direct current cardioversion (DCC). The fourth type, longstanding persistent AF, is 
diagnosed when AF has been present for more than one year. The last type, permanent AF, 
is said to exist when the presence of the arrhythmia is accepted by the patient and physician 
(34).  
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Figure 11: Management Strategies for Atrial Fibrillation. Source: Br J cardiol 2003 
 
 
Acute AF (less than 48 hours of duration): 
If the patient presenting to the emergency department is unwell or hemodynamically 
unstable, the first choice of treatment should be oxygen and emergency cardioversion for 
rhythm control. If cardioversion is unavailable or not possible, then pharmacological 
conversion using amiodarone should be attempted (35).  
For rate control, the first line drugs are diltiazem (60-120 mg / 8 hours orally) or verapamil 
(40-120 mg / 8 hours orally). Second line treatment is digoxin or amiodarone. 
The emergency physician should also start the patient on low molecular weight (LMWH), to 
anticoagulate the patient and prevent mural thrombus formation (37).  
Drug cardioversion is often preferred by physicians, with the most commonly used agent 
being amiodarone, given either IV (5mg/kg over 1 hour, then 900mg over 24 hours) or orally 
(200mg every 8 hours for one week, then 200mg over 12 hours for 1 week, and 100mg over 
24 hours maintenance).  
 
 
Chronic AF (longer than 48 hours of duration) 
The main goal in the treatment of these patients is rate control and anticoagulation. B-
blockers or calcium channel blockers are first line treatments of choice. If the usage of one of 
two drugs is not successful, the physician should add digoxin, then consider amiodarone 
(38).  
Rhythm control is the goal of treatment in younger or symptomatic patients. If the time since 
the onset of AF unknown and if cardioversion has been chosen as the treatment method, 
echocardiography should be performed and the patient have to be pre-treated for 1 week 
with sotalol or Amiodarone, together with anticoagulation (38). If there is a risk of 
cardioversion failure, then pharmacological cardioversion with flecainide should be the next 
best step.  
 
Anticoagulation and AF 
When a patient presents with AF, it is very important to determine the risk of an embolism 
and to start the patient on anticoagulation. The most accurate, and most widely used scoring 
system, is the CHADS2 score (39). 
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CHADS2 score is a clinical prediction system used for estimating the risk of developing a 
stroke in patients with a known AF (39,40). This scoring system determines whether or not 
treatment is required with anticoagulation therapy or antiplatelet therapy (41).  
A higher CHADS2 score corresponds to a greater risk of stroke, while a lower score 
corresponds to a lower risk of stroke.  
Table 3: Abbreviation for CHADS2 and the points awarded for each. VA Palo Alto Medical 
Center and at Stanford University: the Sports medicine Program and the Cardiomyopathy 
Clinic 2007-09-14. 
 Conditions points 
C Cognitive heart failure 1 
H Hypertension >140/90 mmHg 1 
A Age > 75 years  1 
D Diabetes Mellitus 1 
S2 Prior Stroke, or TIA 2 
 
 
 
 
Table 4: Annual stroke risk, in regard to the CHADS2 score. Karthikeyan G, Eikelboom JW. 
The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe? Thromb 
Haemost. 2010 Jul 5;104(1):45-8. 
 
 
 
 
 
 
 
 
 
 
 
 
A score of 0, is considered a low risk patient and require no aspirin or anticoagulants. A 
score of 1 is moderate risk and the patient should be started on aspirin. A score of 2 or 
higher is high risk patients, requiring LMWH or warfarin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHADS2 Score Stroke Risk % 
0 1.9 
1 2.8 
2 4.0 
3 5.9 
4 8.5 
5 12.5 
6 18.2 
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Conclusion 
The understanding and quick recognition of arrhythmias and mastering the treatment is one 
of the most important tasks for an emergency physician (2, 3).  
The diagnosis of arrhythmias can be challenging, especially in stressful conditions like in the 
emergency department. Ideally, the patients should be treated in areas with full access to 
ECG monitoring, oxygen and external defibrillator.  
A good understanding of the diversity of conditions that can predispose a patient, with a 
normal or abnormal heart, to arrhythmias is essential so that a physician can easily choose 
the appropriate treatment method.  
The algorithm that was presented in this thesis and the recommended therapeutic strategies 
should function as a rapid guide for the emergency physician.  
Recognition and early treatment of arrhythmias have a very good prognosis, with a 95% 
success rate.  
 
The most important decision-making criteria in the emergency treatment of cardiac 
arrhythmia are hemodynamic stability or instability in tachycardia and the width of the QRS 
complex. This information serves as a marker for a presumed ventricular or supraventricular 
origin of the disturbance.  
Additionally, all clinical staff working in the emergency department should be trained in basic 
life support, intermediate life support, and ideally, advanced life support.  
 
With the development of modern medicine, our elderly population has been increasing. 
Additionally, the number of obese persons is on the rise. With the increase of these two 
population groups, the prevalence of obesity- and age-related cardiovascular diseases also 
increases.  
The population living with, or suffering from cardiac diseases is more than ever. It is 
estimated that 36% of people post myocardial infarction will present with an arrhythmia within 
two years after their diagnosis (42).  
 
As a result of continuing research and better education, the number of deaths resulting from 
arrhythmias and the number of medical errors have been reduced much more radically than 
was previously possible.  
Cardiology, cardiac pharmacy and cardiac models, are some of the most widely developed 
areas in medicine with continuous research with the goal for a better tomorrow. 
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